Clearmind’s CMND-100 Hits Safety Milestone in AUD Trial
Event summary
- Clearmind’s CMND-100 met primary safety endpoint in Phase I/IIa AUD trial.
- Third cohort showed high tolerability with no serious adverse events at higher dosage.
- Multinational, multicenter study evaluates safety, pharmacokinetics, and preliminary efficacy for moderate to severe AUD.
- Clearmind holds 19 patent families, including 31 granted patents.
The big picture
Clearmind’s positive safety data for CMND-100 reinforces the growing interest in non-hallucinogenic psychedelic treatments for AUD, a market with significant unmet needs. The company’s patent portfolio strengthens its position as it navigates regulatory hurdles and competes with other biotechs developing similar therapies.
What we're watching
- Regulatory Pathway
- How FDA approval timelines will impact CMND-100’s commercialization.
- Competitive Positioning
- Whether Clearmind can differentiate itself in the psychedelic therapeutics space.
- Clinical Progression
- The pace at which subsequent trial phases will advance CMND-100 toward market readiness.
Related topics